/ /

Cheryl Guttman Krader
Vitrectomy offers a viable therapeutic option for DME
Maurice B. Landers III, MD, presents an argument that in an era when pharmacological therapy has become the mainstay for the treatment of diabetic macular edema (DME), pars plana vitrectomy (PPV) deserves consideration as a reasonable alternative for early DME in appropriate patients.
Identifying glaucoma-related visual function loss
A portable device for detecting multifocal steady-state visual evoked potentials associated with visual field stimulation is being developed as an objective test for identifying glaucoma-related visual function loss.
Treat-and-extend protocol reduces burden of anti-VEGF treatment for DME
Results of the prospective TREX-DME study provide an evidence base for using a treat-and-extend protocol for administering anti-VEGF injections for eyes with diabetic macular edema.
Suprachoroidal corticosteroid shows visual, anatomic improvements in DME eyes
Suprachoroidal triamcinolone acetonide (CLS-TA, Clearside Biomedical) injection resulted in visual and anatomic improvements in eyes with diabetic macular edema, particularly in those that were treatment-naïve. Multiple injections of the investigational treatment were well-tolerated and associated with a low incidence of IOP elevation.
Lens fragmentation device is in the loop
A micro-interventional device that uses a nitinol filament can dissect any grade cataract without causing capsular stress.
Customized CXL approach brings outcomes benefits
Customized corneal crosslinking for keratoconus focuses the treatment on the weak area of the cornea.